FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382933719> ?p ?o ?g. }

• W4382933719 endingPage "554" @default.
• W4382933719 startingPage "546" @default.
• W4382933719 abstract "Introduction Sarcomatoid renal cancer (sRCC) patients have poor outcomes. EA1808 evaluated sunitinib and gemcitabine (SG) and sunitinib alone (S) in sRCC in a randomized cooperative group phase II trial (NCT01164228). Patients and Methods Pts were aggregated 1:1 to SG (45 pts) or S (40 pts) using a 2-stage design. sRCC pts with ≤ 1 prior nonvascular endothelial growth factor tyrosine kinase inhibitor were stratified into prognostic groups: good (clear cell, < 20% sarcomatoid, PS 0), intermediate (20%-50% sarcomatoid, PS 0), and poor (nonclear cell or > 50% sarcomatoid or PS 1). The primary endpoint was response rate (RR). For SG, the null RR was 15% and a 30% RR was of interest. For S, a 20% RR was of interest vs. a 5% null rate. Secondary endpoints were progression-free survival, overall survival, and safety. Results Both arms met protocol criteria for stage 2 of accrual. A total of 47 pts were randomized to SG and 40 to S. The SG arm had 9 of 45 evaluable patient responses (RR of 20%; CI = [13%-31%]) not meeting the predetermined threshold for success. The sunitinib arm met its endpoint with 6/37 (RR of 16%; CI = [9%-27%]) evaluable responses. Grade ≥ 3 events were experienced by 36 in the SG arm and 17 in the sunitinib arm Conclusions EA1808 was the largest and first randomized cytotoxic trial for sarcomatoid RCC. Sunitinib alone but not the SG met the preset threshold of success. Cytotoxic chemotherapy is only useful in limited clinical scenarios for sRCC." @default.
• W4382933719 created "2023-07-04" @default.
• W4382933719 creator A5001783218 @default.
• W4382933719 creator A5003177689 @default.
• W4382933719 creator A5007052233 @default.
• W4382933719 creator A5021900842 @default.
• W4382933719 creator A5032422193 @default.
• W4382933719 creator A5033346506 @default.
• W4382933719 creator A5035665916 @default.
• W4382933719 creator A5045746656 @default.
• W4382933719 creator A5046123003 @default.
• W4382933719 creator A5055923107 @default.
• W4382933719 creator A5060006096 @default.
• W4382933719 creator A5069070518 @default.
• W4382933719 creator A5071194144 @default.
• W4382933719 creator A5071707664 @default.
• W4382933719 creator A5090879940 @default.
• W4382933719 date "2023-10-01" @default.
• W4382933719 modified "2023-10-14" @default.
• W4382933719 title "Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808" @default.
• W4382933719 cites W1583423320 @default.
• W4382933719 cites W1949140443 @default.
• W4382933719 cites W1965732727 @default.
• W4382933719 cites W1968928563 @default.
• W4382933719 cites W2025597777 @default.
• W4382933719 cites W2041902889 @default.
• W4382933719 cites W2082746319 @default.
• W4382933719 cites W2086273452 @default.
• W4382933719 cites W2091889350 @default.
• W4382933719 cites W2113140565 @default.
• W4382933719 cites W2113322173 @default.
• W4382933719 cites W2131444088 @default.
• W4382933719 cites W2136088692 @default.
• W4382933719 cites W2147382551 @default.
• W4382933719 cites W2442006256 @default.
• W4382933719 cites W2787776480 @default.
• W4382933719 cites W2792937256 @default.
• W4382933719 cites W2913745075 @default.
• W4382933719 cites W2917394191 @default.
• W4382933719 cites W2972396084 @default.
• W4382933719 cites W3081958456 @default.
• W4382933719 cites W3100362736 @default.
• W4382933719 cites W3109157639 @default.
• W4382933719 cites W3131063362 @default.
• W4382933719 cites W3134949580 @default.
• W4382933719 cites W3216520672 @default.
• W4382933719 cites W4205710681 @default.
• W4382933719 cites W4206841660 @default.
• W4382933719 cites W4221029317 @default.
• W4382933719 cites W4226292283 @default.
• W4382933719 cites W4319293008 @default.
• W4382933719 cites W852189269 @default.
• W4382933719 doi "https://doi.org/10.1016/j.clgc.2023.06.012" @default.
• W4382933719 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37455214" @default.
• W4382933719 hasPublicationYear "2023" @default.
• W4382933719 type Work @default.
• W4382933719 citedByCount "0" @default.
• W4382933719 crossrefType "journal-article" @default.
• W4382933719 hasAuthorship W4382933719A5001783218 @default.
• W4382933719 hasAuthorship W4382933719A5003177689 @default.
• W4382933719 hasAuthorship W4382933719A5007052233 @default.
• W4382933719 hasAuthorship W4382933719A5021900842 @default.
• W4382933719 hasAuthorship W4382933719A5032422193 @default.
• W4382933719 hasAuthorship W4382933719A5033346506 @default.
• W4382933719 hasAuthorship W4382933719A5035665916 @default.
• W4382933719 hasAuthorship W4382933719A5045746656 @default.
• W4382933719 hasAuthorship W4382933719A5046123003 @default.
• W4382933719 hasAuthorship W4382933719A5055923107 @default.
• W4382933719 hasAuthorship W4382933719A5060006096 @default.
• W4382933719 hasAuthorship W4382933719A5069070518 @default.
• W4382933719 hasAuthorship W4382933719A5071194144 @default.
• W4382933719 hasAuthorship W4382933719A5071707664 @default.
• W4382933719 hasAuthorship W4382933719A5090879940 @default.
• W4382933719 hasConcept C121608353 @default.
• W4382933719 hasConcept C126322002 @default.
• W4382933719 hasConcept C126894567 @default.
• W4382933719 hasConcept C143998085 @default.
• W4382933719 hasConcept C168563851 @default.
• W4382933719 hasConcept C203092338 @default.
• W4382933719 hasConcept C2777472916 @default.
• W4382933719 hasConcept C2778439243 @default.
• W4382933719 hasConcept C2778820342 @default.
• W4382933719 hasConcept C2779490328 @default.
• W4382933719 hasConcept C2780258809 @default.
• W4382933719 hasConcept C71924100 @default.
• W4382933719 hasConceptScore W4382933719C121608353 @default.
• W4382933719 hasConceptScore W4382933719C126322002 @default.
• W4382933719 hasConceptScore W4382933719C126894567 @default.
• W4382933719 hasConceptScore W4382933719C143998085 @default.
• W4382933719 hasConceptScore W4382933719C168563851 @default.
• W4382933719 hasConceptScore W4382933719C203092338 @default.
• W4382933719 hasConceptScore W4382933719C2777472916 @default.
• W4382933719 hasConceptScore W4382933719C2778439243 @default.
• W4382933719 hasConceptScore W4382933719C2778820342 @default.
• W4382933719 hasConceptScore W4382933719C2779490328 @default.
• W4382933719 hasConceptScore W4382933719C2780258809 @default.
• W4382933719 hasConceptScore W4382933719C71924100 @default.
• W4382933719 hasFunder F4320317664 @default.

• next